El Mowassat University hospital
Alexandria, Egypt
NCT Number: NCT04085562
Hypertension is highly prevalent in hemodialysis (HD) patients and leads to increased morbidity and mortality due to cardiovascular disease(CVD). Left ventricular hypertrophy (LVH) is both a manifestation of hypertension caused end-organ damage and an independent risk factor for CVD. Evidence shows that Beta-blockers, especially of low dialyzability decrease risk of CVD and mortality. Calcium channel blockers (CCBs) were also shown to effectively control BP in the volume expanded state and reduce cardiovascular disease risk. Asymmetric dimethyl arginine (ADMA) is a uremic toxin that decreases NO synthesis and is correlated to LVH, carotid intimal thickness (CIT), CVD, and mortality. Amlodipine is shown in one study to significantly reduce ADMA level in HD patients. The purpose of this study is to determine the effect of calcium channel blocker Amlodipine compared to Beta-blocker Bisoprolol on regression of LVH, reduction of ADMA plasma level and on BP control among hypertensive patients on HD.
Looking for future studies?
Notify Me18 year–85 year
All sexes
Interventional
Phase 4
Alexandria, Egypt
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Bisoprolol as antihypertensive drug in patients on hemodialysis
Amlodipine as antihypertensive drug in patients on hemodialysis
Time frame: 6 months
Time frame: 6 months
Alexandria University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02095691
Cardiovascular Diseases, Female Urogenital Diseases
View Trial DetailsNCT01756300
Cardiovascular Diseases, Essential Hypertension
View Trial DetailsNCT05807711
Cardiovascular Diseases, Chronic Disease
Alexandria, Alexandria Governorate, Egypt
View Trial DetailsNCT05001945
Cardiovascular Diseases, Female Urogenital Diseases
Lincoln, California, United States
View Trial Details